Case Reports in Hematology

Case Reports in Hematology / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 8274732 |

Madiha Iqbal, Rabia Saleem, Salman Ahmed, Prachi Jani, Salvador Alvarez, Han W. Tun, "Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review", Case Reports in Hematology, vol. 2018, Article ID 8274732, 5 pages, 2018.

Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review

Academic Editor: Massimo Breccia
Received11 May 2018
Revised20 Aug 2018
Accepted27 Aug 2018
Published16 Sep 2018


Phlegmonous gastritis is an uncommon acute bacterial infection of the stomach that carries a fatal prognosis in spite of the advent of antibiotics. A high index of suspicion is required in patients with risk factors. An immunocompromised state is identified as one of the most important risk factors. We hereby report a case of successful antimicrobial treatment of phlegmonous gastritis in a patient who was receiving intensive chemotherapy for acute myelogenous leukemia. We have also carried out a review of literature over the past ten years. Streptococcus pyogenes is identified as the most common causative organism, and patient presentation is usually nonspecific. Conservative treatment with prompt institution of antibiotics can lead to rapid resolution in the majority of patients.

1. Introduction

Phlegmonous gastritis (PG) is a rare acute bacterial infection, which primarily involves the submucosal layer of the stomach wall, but can also involve the muscularis layer and rarely the mucosa [13]. It is rapidly fatal if untreated and thus requires prompt diagnosis and management. Even with the correct diagnosis and antimicrobial therapy, the mortality rate remains high at 27–40% [2, 3]. PG primarily affects the middle-aged population of 45–74 years, with a 65% male predominance [4]. The underlying etiology is largely unknown, although an immunocompromised state associated with malignancy, chemotherapy-induced neutropenia, acquired immunodeficiency syndrome (AIDS), alcoholism, and immunosuppressive drugs is considered an important risk factor [5]. We herein report a patient who developed PG in the setting of prolonged neutropenia related to relapsed acute myeloid leukemia (AML) and intensive chemotherapy and was successfully treated with systemic antimicrobial therapy.

2. Case Presentation

The patient reported is a 56-year-old woman who was diagnosed with acute myeloid leukemia (AML) with cytogenetic abnormality of inversion 16 in 2013. She achieved a complete remission (CR) after standard induction chemotherapy with 7 + 3 regimen consisting of ara-C and daunorubicin followed by consolidation with high-dose ara-C (HiDAC). She relapsed a year later and was re-induced with a salvage chemotherapy regimen MEC (mitoxantrone, etoposide, and cytarabine) achieving a second CR, which was followed by a matched unrelated allogeneic stem cell transplant (allo-SCT). Her posttransplant course was uneventful without significant graft versus host disease and prolonged requirement for immunosuppression. Two years after allo-SCT, she had a central nervous system (CNS) relapse of her original leukemia and presented with an infiltrating lesion in the lumbosacral spine; her CSF cytology was positive for myeloblasts. She was admitted to the hospital to receive reinduction chemotherapy; her vitals upon admission were as follows: temperature 37.7 °C, blood pressure (BP) 129/65 mmHg, heart rate (HR) 72/min, and respiratory rate (RR) 14/min. She was started on intrathecal chemotherapy with ara-C and systemic chemotherapy with the salvage chemotherapy regimen FLAG-IDA (fludarabine, ara-C, and idarubicin). The day chemotherapy started for the patient was noted as day 1. On day 10, the patient developed neutropenic fever, and the white blood count (WBC) noted to be <0.1 × 109/L with absolute neutrophil count (ANC) of 0. She was started on intravenous (IV) cefepime 2 g every 8 hour after evaluation for underlying infectious etiology was done. The work up did not isolate any organism and included blood culture, urine culture, and chest X-ray. On day 16, the patient developed left upper quadrant abdominal pain. Vital signs then were as follows: maximum temperature (Tmax) 37.5°C, along with HR of 80–94/min, RR 16–18/min, and BP SBP 105–126/DBP 55–71 mmHg. Her blood tests then were as follows: WBC <0.1 × 109/L, ANC 0, hemoglobin 8.0 g/dl, platelet 12 × 109/L, and serum blood chemistry and liver function tests were noted to be without significant derangements. A CT scan of the abdomen was performed that showed diffuse thickening of stomach wall (Figure 1(a)), concerning for infectious or infiltrative malignant process. Her absolute neutrophil count had been at the nadir for 10 days prior to this development. Her antimicrobial coverage was increased to include anaerobic coverage by changing her antibiotic regimen from IV cefepime 2 g every 8 hour to IV piperacillin/tazobactam 3.375 g every 6 hour, leading to short-lived symptomatic improvement for roughly two weeks. Upon symptom recurrence, the patient was noted to be febrile with Tmax of 39.5°C, along with HR of 109–139/min, RR 18–20/min, and BP SBP 94–124/DBP 55–71. Two sets of peripheral blood cultures were drawn which did not show growth of any organism after 5 days of incubation. The patient continued to remain hemodynamically stable.

An upper gastrointestinal (GI) endoscopy was performed which showed a large ulcerative lesion with purulent discharge and inflammatory changes (Figure 2). Citrobacter freundii, Enterococcus faecalis, and Bacillus cereus were isolated from culture on gastric biopsies. Imaging, endoscopic, and microbiological findings were consistent with phlegmonous gastritis.

Infectious disease service was consulted, IV piperacillin/tazobactam 3.375 g every 6 hour was stopped, and the antibiotic regimen was changed to IV vancomycin (managed per pharmacy protocol based on weight and renal function) and IV meropenem 1 g IV every 8 hour. The recommendation for broad coverage of microorganisms was made by infectious disease service, given the high risk of mortality associated with phlegmonous gastritis. Prophylactic antifungal and antiviral for neutropenia were continued. Organism susceptibilities were carried out for Citrobacter freundii and Enterococcus faecalis, which revealed Citrobacter freundii to be resistant to ampicillin, cefazolin, and cefuroxime, while Enterococcus faecalis was noted to be pansensitive. Per organism susceptibility and with the help of infectious disease service, her antibiotic regimen was changed to IV cefepime 2 g every 8 hour, IV metronidazole 500 mg IV every 8 hour, and IV vancomycin per pharmacy protocol. This antibiotic regimen was continued for a total of two weeks. The patient’s gastrointestinal symptoms resolved quickly, and she was able to resume normal diet. Follow-up CT scan a month later showed marked improvement in gastric thickening (Figure 1(b)). She is currently doing well with her AML in remission and no recurrence of her GI symptoms.

3. Discussion and Literature Review

Phlegmonous gastritis is a rare infection with less than 500 cases reported in literature [3]. We have carried out a bibliographical search using PubMed from 2007 to 2017 using the keyword “Phlegmonous Gastritis” and found 36 articles, in English, Spanish, and Japanese, of which we reviewed 25.

Our limited data review showed that there have been only 4 cases reported in the USA and 3 in Europe in the last 10 years, whereas the bulk was reported in Southeast Asia, namely Japan (13) and Korea (8). In addition to an immunocompromised state, the other reported risk factors are increased age, gastric mucosal injury from chronic gastritis, peptic ulcer, endoscopic procedures, gastric cancer, achlorhydria, infection, and malnutrition [6, 7]. Our review found malignancy to be a risk factor in 32% of the cases (8/25). The mortality rate has been reported to be higher in groups with an identified risk factor as compared to those without one [8]. PG has been further classified into primary and secondary types [1]. The primary type is usually idiopathic or occurs after direct damage to the gastric mucosa due to trauma, cancer, and endoscopic interventions, thereby leading to direct microbial invasion. The secondary type is either associated with infection of neighboring organs, such as infection due to pancreatitis, hepatic abscess, and cholecystitis, or hematogenous/lymphogenous spread from other organs.

PG is a rare infection that usually presents with nonspecific gastrointestinal symptoms. A high index of suspicion is necessary, especially in immunocompromised individuals. Epigastric/abdominal pain is the most common symptom, with other symptoms including but not limited to being fever, nausea, vomiting, and, less often, diarrhea and hematemesis [6]. PG should be highly suspected if a CT scan shows diffuse thickening of the stomach wall. The upper GI endoscopy should be performed as visual and microbiologic findings help establish the diagnosis and guide antimicrobial therapy. Although, Streptococcus pyogenes is the most frequently reported isolated organism in about 70% of cases, polymicrobial infection as seen in our patient is also quite common [2, 8, 9]. Our review of cases followed a similar pattern, wherein Streptococcus spp. was the most common pathogen identified in 44% of cases, but there were also other uncommon pathogens isolated such as Citrobacter, Acinetobacter, Enterobacter spp., and Bacillus spp., and even resistant pathogens like MDR (multidrug-resistant) Streptococcus and VRE (vancomycin-resistant enterococcus) (Table 1).

Author/YearSexAgeCause/risk factorSymptomsPathogen/sDiagnosisIntervention/managementComplicationsResult

Ajibe H, 2008M74Endoscopic submucosal dissection for gastric adenocarcinomaEpigastric pain, feverCitrobacter freundii, Enterobacter cloacae, and StreptococcusCT, EGD, EUSAntibiotics, total gastrectomyNilDischarge
Alonso et al., 2013 [7]F55NoneChest painStreptococcus pyogenesCTAntibiotics, endoscopic abscess drainageNilDischarge
Fan JQ, 2013M65Esophagectomy for esophageal adenocarcinomaFever, dyspneaNilCT, EGDAntibioticsNilDischarge
Flor-de‐Lima F, 2015M7Acute tonsillitisEpigastric pain, nausea, vomitingStreptococcus pneumoniae, EBVCT, EGD with biopsyAntibioticsNilDischarge
Guo et al., 2009 [3]M57CML, myeloid sarcomaDyspnea, chest pain, abdominal pain, fatigueVRECT, EGD with biopsy, autopsyAntibioticsUpper GI bleedDeath
Huang et al., 2017 [5]F60Uncontrolled DMFever, fatigue, chest painPseudomonas, KlebsiellaCT, EGDAntibiotics, surgery (not gastrectomy)Hypopharyngeal abscess, esophageal perforationDischarge
Ishigami T, 2008M70NoneFever, abdominal painMDR StreptococcusEGDAntibioticsNilDischarge
Itonaga M, 2012F70EUS-FNA for pancreatic tumorFever, abdominal painAlpha-hemolytic StreptococcusCt, EGD, EUSAntibioticsNilDischarge
Kato et al., 2015 [1]M64DM, chronic pancreatitisEpigastric pain, nauseaPeptostreptococcusCT, EGD with biopsyAntibiotics, EUS-guided pseudocyst drainageNilDischarge
Kim BY, 2017M51Ankylosing spondylitisNausea, vomitingNilCT, EGDAntibioticsNilDischarge
Kim et al., 2010 [9]M48Alcoholism, uncontrolled DMFever, chest pain, abdominal pain, dyspneaKlebsiella spp.EGDAntibiotics, surgery (not gastrectomy)Bilateral pleural effusionsDischarge
Kim et al., 2016 [2]M74Alcoholic cirrhosis, DM, recent EGD, gastric adenocarcinomaAbdominal pain, vomitingNilCT, EGD with biopsyAntibioticsNilDischarge
Kim NY, 2011M66NoneEpigastric pain, nausea, vomitingKlebsiella, AcinetobacterCT, EGD with biopsyAntibioticsNilDischarge
Liu YJ, 2013M84Colon cancer, prostate cancerFever, nausea, vomitingPolymicrobial (gram positive and gram negative organisms)CT, exploratory laparotomy gastric biopsyAntibiotics, gastrectomyNilDischarge
Matsumoto H, 2015M74Myelofibrosis, multiple myeloma, neutropeniaEpigastric pain, nauseaBacillus spp.CT, EGDAntibioticsSepsis, disseminated intravascular coagulationDeath
Min et al., 2014 [6]F51Gastric ulcerAbdominal painStreptococcus pyogenesCT, exploratory laparotomyAntibiotics, total gastrectomyGastric submucosal dissectionDischarge
Morimoto et al., 2014 [4]M77DM, gastric ulcersFever, nausea, vomitingGroup A StreptococcusCTAntibioticsDeath
Nomura K, 2015F80NoneEpigastric pain, vomitingEnterobacter cloacae and Enterococcus faeciumCT, EGD with biopsyAntibiotics, total gastrectomy (worsening gastric strictures)NilDischarge
Paik DC, 2010M45Recent paranasal sinus surgeryAbdominal pain, nausea, vomitingStreptococcus pyogenesCT, exploratory laparotomy EGDAntibioticsRespiratory failure, renal failure, coagulopathyDischarge
Park CW, 2010F73Gastric outlet narrowingEpigastric pain, abdominal distensionE. coli, AcinetobacterCT, EGD with biopsyAntibiotics, pyloric stentNilDischarge
Rada-Palomino et al., 2014 [8]M62HIVEpigastric pain, hematemesis, diarrheaStreptococcus pyogenesCT, EGD with biopsyAntibioticsNilDischarge
Saito M, 2012F55ALLNeutropeniaBacillus spp.CT, EGD with biopsyAntibioticsNilDischarge
Sakata T, 2011F63NoneFeverNone reportedCT, EGD with biopsyAntibiotics, drainageNilDischarge
Shiozawa K, 2009M62Uncontrolled DMEpigastric painNone reportedCTAntibiotics, drainageNilDischarge
Munroe CA, 2010M58Chronic hepatitis BEpigastric pain, nausea, feverAlpha-hemolytic StreptococcusCT, EGD, EUS with biopsyAntibiotics, aspirationNilDischarge

CML: chronic myeloid leukemia; DM: diabetes mellitus; HIV: human immunodeficiency virus; ALL: acute lymphoblastic leukemia; EBV: Epstein-Barr virus, VRE: vancomycin-resistant Enterococcus; MDR: multidrug resistance; Strep: Streptococcus; EUS: endoscopic ultrasound; CT: computed tomography; EGD: esophagogastroduodenoscopy; FNA: fine needle aspiration.

It is imperative to initiate empiric broad-spectrum antimicrobial coverage as soon as there is the clinical suspicion of possible phlegmonous gastritis, followed by adjustments as per microbiological culture results and clinical course. Early diagnosis and prompt institution of antibiotics has been shown to prevent patient mortality and defer the need of a surgical intervention [7]. All of the patients in our review received antibiotics, with resolution seen in 22/25 (88%) of the cases and death in 3/25 of the cases (12% mortality). This illustrates that prompt recognition and awareness of phlegmonous gastritis as possible complication of prolonged neutropenia in patients with hematological malignancies can clearly impact outcomes.

Invasive modality for management includes surgical gastrectomy and is mainly reserved for those with impending local complications such as perforation or sepsis [6, 7]. As mentioned above if promptly recognized, majority of the patients can be treated via conservative measures. Patients with hematologic malignancies are a unique population that is extremely susceptible to this complication due to prolonged neutropenia, secondary to intensive chemotherapy regimens. Prompt intervention and assistance from multiple medical specialties is needed to prevent fatality from this aggressive infection. Our case highlights the need for awareness of this rare infectious complication amongst health care professionals who take care of immunocompromised patients especially those suffering from hematological malignancies as knowledge of this rare complication can clearly impact patient mortality. Table 1 shows the major clinical characteristics, imaging findings, microbiology results, treatment, and survival outcomes from our literature review.

Conflicts of Interest

The authors declare that that there are no conflicts of interest regarding the publication of this paper.


  1. K. Kato, K. Tominaga, S. Sugimori et al., “Successful treatment of early-diagnosed primary phlegmonous gastritis,” Internal Medicine, vol. 54, no. 22, pp. 2863–2866, 2015. View at: Publisher Site | Google Scholar
  2. K. H. Kim, C. G. Kim, Y. W. Kim et al., “Phlegmonous gastritis with early gastric cancer,” Journal of Gastric Cancer, vol. 16, no. 3, pp. 195–199, 2016. View at: Publisher Site | Google Scholar
  3. J. Guo, S. K. Young, C. R. Lorenzo et al., “Phlegmonous gastritis in a patient with myeloid sarcoma: a case report,” Applied Immunohistochemistry & Molecular Morphology, vol. 17, no. 5, pp. 458–462, 2009. View at: Publisher Site | Google Scholar
  4. M. Morimoto, S. Tamura, T. Hayakawa et al., “Phlegmonous gastritis associated with group A streptococcal toxic shock syndrome,” Internal Medicine, vol. 53, no. 22, pp. 2639–2642, 2014. View at: Publisher Site | Google Scholar
  5. Y. C. Huang, C. Y. Cheng, C. Y. Liao, C. Hsueh, Y. S. Tyan, and S. Y. Ho, “A rare case of acute phlegmonous esophagogastritis complicated with hypopharyngeal abscess and esophageal perforation,” American Journal of Case Reports, vol. 18, pp. 125–130, 2017. View at: Publisher Site | Google Scholar
  6. S. Y. Min, Y. H. Kim, and W. S. Park, “Acute phlegmonous gastritis complicated by delayed perforation,” World Journal of Gastroenterology, vol. 20, no. 12, pp. 3383–3387, 2014. View at: Publisher Site | Google Scholar
  7. J. V. Alonso, J. J. de la Fuente Carillo, M. A. Gutierrez Solis, F. J. Vara Morate, and D. J. Lopez Ruiz, “Gastric wall abscess presenting as thoracic pain: rare presentation of an old disease,” Annals of Gastroenterology, vol. 26, no. 4, pp. 360–362, 2013. View at: Google Scholar
  8. A. Rada-Palomino, A. Munoz-Duyos, N. Perez-Romero et al., “Phlegmonous gastritis: a rare entity as a differential diagnostic of an acute abdomen. Description of a case and a bibliographic review,” Revista Española de Enfermedades Digestivas, vol. 106, no. 6, pp. 418–424, 2014. View at: Google Scholar
  9. H. S. Kim, J. H. Hwang, S. S. Hong et al., “Acute diffuse phlegmonous esophagogastritis: a case report,” Journal of Korean medical science, vol. 25, no. 10, pp. 1532–1535, 2010. View at: Publisher Site | Google Scholar

Copyright © 2018 Madiha Iqbal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1164 Views | 414 Downloads | 2 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.